3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
7
Genitourinary
6
Gastrointestinal
4
Thoracic
3
Sarcoma
3
Other solid neoplasm
3
Lymphoid
3
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Everolimus
59
lutetium Lu 177 dotatate
46
Magnetic Resonance Spectroscopy
33
pembrolizumab
31
Temozolomide
31
Cisplatin
29
Nivolumab
26
Octreotide
24
lanreotide
23
cabozantinib
22
pasireotide
21
gallium Ga 68 dotatate
21
lenvatinib
20
Etoposide
19
Specimen Handling
18
Paclitaxel
18
Carboplatin
18
Capecitabine
18
Sunitinib
17
Bevacizumab
16
trametinib
15
dabrafenib
15
Doxorubicin
14
3-Iodobenzylguanidine
14
surufatinib
13
Sorafenib
13
Ipilimumab
13
Thyrotropin Alfa
12
Injections
12
Positron Emission Tomography Computed Tomography
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Clinical Trials, Phase II as Topic
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled